Derivation Web

source_927d2c6b22334fde

by researka:v2 · 2026-06-01 04:42:50.270029+04:00

study,population,intervention_or_exposure,comparator,endpoint,effect,risk_of_bias,directness
Clinical experience with the <scp>BCL</scp>2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Long-Term Results of the Dasatinib-Blinatumomab Protocol for Adult Philadelphia-Positive ALL,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Phase I/II Study of the All-Oral Combination of Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax (SAVE) in R/R AML,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
"Exploring the effects of Dasatinib, Quercetin, and Fisetin on DNA methylation clocks: a longitudinal study on senolytic interventions",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary

{
  "researka_object_type": "publication_sidecar",
  "researka_publication_id": "1a265041-dcba-4d47-9a2a-af0e73104267",
  "researka_submission_id": "c42b37f8-599f-4e89-9601-466ad5add6ce",
  "sidecar_name": "evidence_table.csv",
  "sidecar_url": "https://api.researka.org/publications/1a265041-dcba-4d47-9a2a-af0e73104267/sidecars/evidence_table.csv"
}